Quick Facts: Therapeutic Domains

• Relieves symptoms associated with anxiety.
• May be used for the management of depression.
• A common approach for managing alcohol withdrawal syndrome.

---

Тофизопам (Tofisopam) is a medication that may be considered for the management of certain mental and nervous system conditions. Its primary purpose is to address symptoms related to anxiety disorders, helping to mitigate the associated tension, unease, and vegetative (physical) symptoms.

The medication is also utilized in the management of depression, where it may contribute to overall symptom relief. In addition, its use is well-established as a therapeutic option to help manage the agitation and physical withdrawal symptoms associated with alcohol dependence syndrome. It is also indicated in some regions for managing mild mental disorders such as neurasthenia.

Furthermore, Тофизопам may be employed to address specific aspects of autonomic nervous system disorders.

Тофизопам is an anxiolytic medicine whose use is governed by specific eligibility rules established in official governmental regulatory documentation.

Contraindicated Populations (Must Not Use)

Use of Тофизопам is strictly contraindicated for individuals with a known hypersensitivity or allergic reaction to Tofisopam or any other drug within the benzodiazepine class. The medicine must also not be used by patients with acute narrow-angle glaucoma, severe hepatic (liver) impairment, or severe respiratory failure.

Restricted and Ineligible Groups

• Age: The drug is intended for use in adults only (typically ge 18 years of age). It is contraindicated in children and adolescents as safety and efficacy have not been established.
• Reproductive Status: The medicine is contraindicated during the first trimester of pregnancy and throughout the entire breastfeeding period.
• Specific Conditions: Caution is required in patients with renal (kidney) impairment, uncompensated chronic respiratory insufficiency, and organic brain damage. It is generally not recommended for patients with chronic psychosis or conditions involving phobias/fear due to the potential risk of increasing certain behavioral symptoms.

The official regulatory profile for Tofisopam documents specific interaction patterns concerning metabolism, plasma concentration, and physiological effects.

Formal Restrictions

Co-administration is formally prohibited with the immunosuppressant medicines Tacrolimus, Sirolimus, and Cyclosporine.

Pharmacokinetic and Exposure Interactions

The metabolism of Tofisopam is subject to alteration by other substances. Co-administration with enzyme inhibitors, such as certain antifungal agents (e.g., Ketoconazole, Itraconazole) or Oral Contraceptives, may increase Tofisopam plasma concentrations due to inhibited breakdown. Conversely, Liver Enzyme Inducers (e.g., Barbiturates) or Nicotine may accelerate Tofisopam metabolism, leading to a reduction in plasma concentrations. Tofisopam may also increase the plasma concentrations of co-administered medicines, including Digoxin and the anticoagulant Acenocoumarol.

Pharmacodynamic Potentiation

Concomitant use with other Central Nervous System (CNS) depressants (such as analgesics, anesthetics, and certain antidepressants) may result in the enhancement of the effects of both substances. Use with Warfarin may affect the anticoagulant effects.

Other Substance Constraints

Consumption of Alcohol is restricted as it may intensify the medicinal effects of Tofisopam. Co-administration with Antacids may affect the absorption of Tofisopam, suggesting a need for dose separation.

Тофизопам acts primarily as an isoenzyme-selective inhibitor of multiple phosphodiesterases (PDEs), enzymes that hydrolyze intracellular cyclic nucleotides. It exhibits the highest affinity for PDE-4A1 and PDE-10A1, followed by PDE-3 and PDE-2A3.

By inhibiting these enzymes in neural tissue and elsewhere, Tofisopam prevents the degradation of the second messengers, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). The resultant accumulation of cAMP and cGMP initiates a downstream protein kinase cascade, involving enzymes like protein kinase A (PKA) and protein kinase G (PKG). This sequence leads to the altered phosphorylation of specific intracellular proteins and transcription factors. The overall systemic physiological consequence of this combined partial inhibition of multiple PDE isoenzymes includes modulation of central nervous system excitability and influence on the autonomic nervous system.

The administration protocol for Tofisopam is designed to ensure consistent and appropriate use of the medicine. The compound is for the oral route, typically supplied as a 50 mg tablet.

---

Administration Scope

Feature	Guideline
Route of administration	Oral route (per os).
Dosing schedule	Typical daily doses range from 150 mg to 300 mg, administered in divided doses. The maximum daily dose is limited to 300 mg.
Timing in relation to meals (if applicable)	The tablet may be taken with or without food.
Preparation requirements (if applicable)	The tablet should be swallowed whole with an adequate amount of water.
Age-group administration rules	Older adults and those with renal impairment require a dose reduction, typically an approximate two-fold decrease. Use is not recommended for patients under 18 years of age.
Missed-dose rules	If a dose is missed, it must be skipped; the subsequent dose must not be doubled.
Special procedural conditions	Administration is avoided in the late afternoon (e.g., after 3-4 PM) to prevent interference with natural sleep cycles.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral
Frequency pattern	Divided daily use (1 to 3 times per day).
Use-context constraints	Short-term use only, typically restricted to a maximum of 12 weeks total duration.

Resulting procedural structure

Step sequence:

• Intake Method: Swallow the 50 mg tablet whole using an adequate amount of water.
• Dosing Schedule: Administer the prescribed single dose, ensuring the total daily dose does not exceed the 300 mg maximum limit.
• Timing Constraint: Ensure the final daily dose is taken before the late afternoon (before 3-4 PM).

Connection to the overall use protocol (2–4 sentences)

The use protocol is structured around a short-term, divided-dose regimen that defines the maximum daily limit and the required daily frequency. This protocol also incorporates dose adjustments for specific patient populations and imposes a time-of-day restriction on administration to ensure compliance with the drug's properties.

Tofisopam: Recent Clinical Evidence

Unique Pharmacological Profile

Tofisopam is chemically a 2,3-benzodiazepine derivative, setting it apart from classic 1,4-benzodiazepines. Unlike conventional benzodiazepines, studies suggest it does not bind directly to the benzodiazepine binding site of the GABA-A receptor. This difference in action is associated with a distinct clinical profile, lacking the significant sedative, muscle relaxant, anticonvulsant, and amnestic effects typically seen with other drugs in this class.

Research has explored the hypothesis that Tofisopam affects proposed mechanisms by acting as an isoenzyme-selective inhibitor of phosphodiesterases (PDEs), particularly PDE-4A1 and PDE-10A1. This mechanism is thought to contribute to its anxiolytic effect while maintaining cognitive function and alertness.

Summary of Clinical Findings

Multiple clinical trials, including double-blind and placebo-controlled studies, have evaluated Tofisopam's effects on anxiety symptoms. The findings reported that Tofisopam was associated with a significant reduction in anxiety severity when compared to placebo in patients with anxiety and depression. Some trials also noted that the drug's effect was pronounced on somatic (physical) manifestations accompanying anxiety disorders.

Comparative and Safety Observations

A double-blind, randomized crossover pilot study comparing Tofisopam to diazepam and placebo found that Tofisopam and diazepam both demonstrated a greater decrease in anxiety scores (as measured by the Hamilton Anxiety Rating Scale) compared to placebo. Importantly, the study observed that adverse effects and withdrawal symptoms occurred less frequently in the Tofisopam group compared to the diazepam group. This research suggests Tofisopam's anxiolytic activity may be achieved with a distinct safety profile regarding sedation and dependency potential when compared to classic benzodiazepines.

Common questions about Тофизопам (FAQ)

---

Q: What are the common signs of Tofisopam withdrawal?

Regulatory warnings for the benzodiazepine drug class, which Tofisopam belongs to, state that stopping the medicine abruptly or reducing the dosage too quickly can lead to withdrawal reactions. These reactions may include anxiety, seizures, and tremors. Official guidance emphasizes the importance of consulting a healthcare professional to develop a plan for slowly decreasing the dose before discontinuing the medicine.

---

Q: What should I do if I accidentally take too much Tofisopam (overdose)?

In the event of an overdose, regulatory information advises seeking immediate emergency medical treatment. Management of an overdose generally involves clinical observation and supportive care provided by healthcare professionals.

---

Q: I heard that Tofisopam has a different chemical structure. What is the difference between 2,3-benzodiazepine and 1,4-benzodiazepine?

Tofisopam is identified as a 2,3-benzodiazepine derivative, giving it a different pharmacological profile compared to traditional 1,4-benzodiazepines. Studies suggest that, unlike conventional medicines in this class, Tofisopam may not bind directly to the GABAA receptor. This difference is associated with a lack of significant sedative, muscle relaxant, or anticonvulsant effects.

---

Q: What are the most serious side effects I need to watch out for?

The most serious reaction documented in regulatory sources is cholestatic jaundice, a liver-related adverse event. In rare instances, especially for patients with certain pre-existing conditions, the treatment may also induce seizures. If severe or unexpected symptoms occur, immediate medical attention is advised.

---

Q: How long can I safely take Tofisopam?

Official use protocols typically restrict the total duration of treatment to a maximum of 12 weeks, as the medicine is intended for short-term use only.

---

Q: What is the typical starting dose of Tofisopam?

Official guidelines state that the typical daily dose for Tofisopam ranges from 150 mg to 300 mg, administered in doses divided throughout the day. The exact dosage is determined by a healthcare professional based on the specific requirements of the patient.

How to Store and Dispose of Tofisopam

Storage Conditions

Tofisopam tablets must be stored under conditions that maintain the product's integrity and chemical stability. The medicine must be kept in a cool, dry, and dark place and away from heat, direct sunlight, and moisture. The container should be tight and light-resistant. For safety, it is a mandatory requirement that Tofisopam is kept out of the reach of children.

---

Disposal Instructions

Any unused or expired Tofisopam must be handled according to official waste procedures. The remainder of the product should be discarded and not stored once a course of treatment is completed. Disposal of the medicine must comply with all local and national regulations for pharmaceutical waste, which includes precautions against releasing the substance into the environment, such as through wastewater.